Abstract: A pharmacokinetic and bioequivalence evaluation of two norfloxacin oral solutions was carried out in healthy broiler chickens after oral administration according to a single dose, randomized, parallelexperimental design. The two formulations were: Vapcotril-10% (Vapco, Jordan) as a test product and ® Mycomas 10% (Univet, Ireland) as a reference product. The chickens were allotted into 3 equal groups (8 ® chickens/group). Chickens of group 1 and 2 were given a single oral dose of Vapcotril-10% and Mycomas ® 10% at a dose level of 16 mg/kg body weight (bw), respectively after an overnight fasting. Chickens of group ® 3 were given a single intravenous dose of norfloxacin to calculate the systemic bioavailability. Serial blood samples were collected from the left brachial or cutaneous ulnar veins at different time points post drug administration. Norfloxacin concentrations in chicken plasma were determined using a microbiological assay and Klebsiella pneumoniae ATCC 10031 as a test organism. The pharmacokinetics analysis of the data was performed using non-compartmental analysis based on statistical moment theory (SMT) with the help of computerized WinNonlin program (Version 5.2, Pharsight, CA, USA). The maximum plasma concentration (C ), time to reach peak concentration (t ), area under plasma concentration-time curve 
Introduction
Norfloxacin is a flouroquinolone antibacterial agent that is e xtensively used in veterinary medicine practice (Prescott and Baggot, 1993; Sarkozy et al., 2004; Martinez et al., 2006; Cho et al., 2008) . Norfloxacin has a wide range of antibacterial activity against most Gramnegative bacteria, some of Gram-positive aerobes as well as most Mycoplasma and Chlamydia Spp. (Ito et al., 1980; King et al., 1982; Norrby and Jonsson, 1983; Hannan et al., 1989) . In addition, its antibacterial activity may extend to cover those organisms that are resistant to other antibacterial (Vancutsem et al., 1990; Neu and Labthavikul, 1982; Crumplin et al., 1984) . Norfloxacin, like other flouroquinolone, exhibits a bactericidal effect which has been shown to be a concentration-dependent in its rate of killing with a post-antibiotic effect (PAE) against most Gram-negative pathogens (Neu et al., 1987) . Norfloxacin is well absorbed after oral administration, highly lipid-soluble and penetrates tissues very rapidly and often reaching tissue concentrations higher than serum levels (Alestig, 1990) . Because it's distinct pharmacological advantages and broad antibacterial spectrum, norfloxacin became a valuable antibiotic for the treatment of mycoplasmosis, colibacillosis and pasteurellosis in chickens (Laczay et al., 1998) . To obtain marketing approval, generic formulations must demonstrate bioequivalence to the marketed pioneer product in every target animal species included on the pioneer product label (Martinez et al., 2001) . Bioequivalent drug products are generally statistically indistinguishable based on their respective concentration-time profiles for the active drug moiety in the appropriate biological matrix (Riviere, 1994 ). Many studies that described the pharmacokinetics of norfloxacin in broiler chickens and turkeys are currently available (Anadon et al., 1992; Gulkaroc and Ziv, 1994; Ramadan et al., 1994; Laczay et al., 1998; Sarkozy et al., 2002 and 2004) . However, limited published bioequivalence trails were reported. Accordingly, the aim of the current study is to evaluate the pharmacokinetic and bioequivalence of two norfloxacin oral dosage forms (Vapcotril and Mycomas ) in healthy broiler chickens. Experimental animals: Thirty two healthy broiler chickens (Hubbard x Hubbard) of 30-50 days old, moment theory (SMT) as previously described (Gibaldi weighing from 1.8-2.3 kg were used in this study. The chickens were purchased from local poultry farm. They were placed in the animal house at Jordan University of Science and Technology. The animals were monitored for 2 weeks for any apparent clinical signs before drug administration. The animal house temperature was maintained at 25 ± 2 C and humidity at 45-65%. The o chickens had free access to water and antibacterial-free food.
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Materials and Methods
Study products
Experimental design:
The chickens were allotted into 3 equal groups (8 chickens/group). Chickens of group 1 and 2 were given a single oral dose of Vapcotril and ® Mycomas at a dose level of 16 mg/kg bw, respectively. ® Chickens of group 3 were given a single intravenous dose (16 mg/kg bw) of norfloxacin. Chickens were weighted prior drug administration and the doses were calculated accordingly. Norfloxacin was given directly into the crop using a thin plastic tube attached to a syringe for oral administration and in the right brachial vein for intravenous route. Food was withheld for 12 h before drug administration and was offered 6 h after drug administration. Water was provided ad libitum. The study was designed as randomized parallel protocol.
Sample collection: Blood samples (1-1.5 ml) were collected from the left brachial vein or cutaneous ulnar veins into heparinized tubes at 0 (pre-treatment), 5, 10, 15 and 30 min and at 2, 4, 2, 6, 8, 10, 12 and 24 h after intravenous administration and at 0, 10, 20, 30 min and 2, 4, 6, 8, 10, 12 and 24 hours after oral administration All blood samples were centrifuged directly a t approximately 1000 g for 5 min and then the plasma was harvested and stored at -20 C until assayed. o Assay procedure: Chicken plasma samples were assayed for determination of norfloxacin concentrations by microbiological assay as described previously (Bland et al., 1983; Edberg, 1986) using Klebsiella pneumoniae ATCC 10031 as test organism and Mueller-hinton agar (Difco, Detroit, MI, USA). Five wells, 6mm in diameter, were made in a standard Petri-dish plate (120 mm) containing 25 ml inoculated agar. Wells were filled with test plasma samples or norfloxacin standard. Zones of inhibition were measured after 18 h of incubation at 37 C and the concentrations of norfloxacin were o calculated from the standard curve. Standard curves of norfloxacin were prepared in antibacterial-free chicken plasma by the appropriate serial dilution. The standard curve in chicken plasma was linear over the range of 0.2 to 100 µg/ml (the correlation coefficient (R ) = 0.997).
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The limit of quantification was 0.2 µg/ml.
Pharmacokinetic and statistical analysis:
The pharmacokinetics analysis of the data was performed using non-compartmental analysis based on statistical 
Results
The concentrations of norfloxacin in chicken plasma were determined up to 12 h and were not detected in all chickens 24 h post single oral and intravenous administration. The mean concentration-time profile for norfloxacin after oral and intravenous administration is shown in Table 1 and Fig. 1 (Table 3) .
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Discussion
Norfloxacin, is one of the first modern flouroquinolone antimicrobial agents featuring a fluorine atom at C-6 and a piperazine ring at C-7, has increased its potency in relation to other flouroquinolone (Wentland, 1990; Samanidou et al., 2003) . In the current study, w e investigated the pharmacokinetics and bioequivalence of two oral norfloxacin solutions (Vapcotril-10% and ® Mycomas10% ) in healthy broiler chickens at a dose rate ® of 16 mg/kg bw. Norfloxacin concentrations in chicken plasma samples were determined by microbiological assay method that has been previously published (Bland et al., 1986) . This microbiological method does not differentiate between the antimicrobial activity associated with a parent compound or its metabolites (e.g. desethylenenorfloxacin and oxonorfloxacin) or even other microbial growth inhibitors that could be present in a given formulation. Nevertheless, it measures the total activity which could be more useful for pharmacodynamic evaluations than high performance liquid chromatography (HPLC) methods (McKellar et al., 1999; Heinen, 2002) . present study were higher than those reported in healthy broiler chickens (1.46 ± 0.18 µg/ml), turkeys (0.95 ± 0.15 µg/ml) and geese (1.58 ± 0.3 µg/ml) given norfloxacin at a dose level of 10 mg/kg bw (Laczay et al., 1998) . The difference in the dose level in these studies may contribute to the differences in the C . However, our max achieved t for both formulations was in agreement max with those reported in broiler chickens, turkeys and geese (1-2 h) (Laczay et al., 1998) . The lowest concentration of antimicrobials, which inhibit the growth of the target pathogen, is referred to the minimum inhibitory concentration (MIC) (Salmon and Watts, 2000) . The MIC of norfloxacin against the major poultry 90 pathogenic Gram-negative bacteria (E. coli, Salmonella spp., Pasteurella spp.) and mycoplasmas is about 0.25 µg/ml (Hannan et al., 1989; Prescott and Baggot, 1993; Laczay et al., 1998) . In the present experiment, Vapcotril ® and Mycomas plasma concentrations exceeding 0.25 ® µg/ml were maintained for up to 12 h after a single oral administration of both products. Therefore, norfloxacin should be given twice a day at a dose level of 8 mg/kg bw to maintain therapeutic concentrations or continues in water 3-5 days. Following single intravenous administration, the elimination half-life (t ) (3.51±0.17 h) of norfloxacin 1//2$ was shorter than those previously reported in chicken (8.0±0.3) (Anadon et al., 1992) . The total body clearance (Cl ) was 6.0±0.51 ml/min/kg. Whereas, the apparent B volume of distribution (Vd ) and the volume of distribution z at steady state (V ) calculated in the current experiment ss were 1.87±0.24 and 1.46±0.14 l/kg, respectively, indicting a wide norfloxacin distribution in tissues. This bioequivalence study was carried out in healthy broiler chicken under controlled conditions using a parallel design. The 90% confidence interval for the mean ratio AUC , AUC and C were 99.53- 
